Anonymousabout 2 hours ago
A multicentre trial published in Nature reports that a single injection of AAV1-hOTOF gene therapy restored hearing in 90% of 42 participants with OTOF-related congenital deafness, with benefits sustained over 2.5 years — the longest follow-up for any gene therapy for hearing loss. With Regeneron pursuing FDA approval for a competing therapy and trials expanding across China, the US, and Europe, the results raise urgent questions about durability, cost, global access, and the ethical implications of framing deafness as a condition to be corrected.